3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Uveal Melanoma
2
Lymphoma, T-Cell, Cutaneous
2
Lichen Planus, Oral
2
Stomach Neoplasms
1
Retinal Diseases
1
Recurrence
1
Radiodermatitis
1
Pain
1
Neuroma, Acoustic
1
Mycosis Fungoides
1
Melanoma
1
Macular Degeneration
1
Lymphomatoid Papulosis
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Large-Cell, Anaplastic
1
Lymphoma, Follicular
1
Lung Neoplasms
1
Leiomyoma
1
Glioblastoma
1
Fibroma
1
Exanthema
1
Esophageal Stenosis Acquired
1
Dupuytren Contracture
1
Disease
1
Dermatitis, Contact
1
Choroid Diseases
1
Chalazion
1
Castration Resistant Prostate Cancer
1
Breast Neoplasms
1
Adenomyosis
1
Interventions
Gels
2
Fulvestrant
2
Doxycycline
2
Dapsone
2
ruxolitinib
1
dexpanthenol
1
ceterizine hydrochloride
1
capivasertib
1
benralizumab
1
Triamcinolone Acetonide
1
Tetracycline
1
Sirolimus
1
Provitamins
1
Prednisone
1
Panitumumab
1
Minocycline
1
Loperamide
1
Irinotecan
1
IFL protocol
1
Hydrocortisone
1
Erlotinib Hydrochloride
1
Clindamycin
1
Cetuximab
1
Anti-Bacterial Agents
1
Alpelisib
1
Acitretin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Exanthema
×
Triamcinolone Acetonide
×
Clear all
NCT00473083
2017-04-04
LUTRAERL
British Columbia Cancer Agency
Phase 2
Completed
150 enrolled
13 charts